参考文献/References:
1 余永利.不摄取131I的甲状腺癌治疗.国外医学·放射医学核医学分册,2005,29(2):57-63.
2 Bravo SB,Gac?a-Rendueles MER,Seoane R,et al,Plitidepsin has a cytostatic effect in human undifferentiated(anaplastic) thyroid carcinoma.Clin Cancer Res,2005,11(21):7664-7673.
3 Cengic N,Bakw CH,Schütz M, et al.A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-apecific sodium iodide symporter gene expression.J Clin Endocrinol Metab,2005,90(8):4457-4464.
4 王深明,甲状腺癌的基因治疗.外科理论与实践,2003,8(4):286-288.
5 Kogai T,Tati K,Brent GA.Enhancement sodium/iodide symporter expression in thyroid,and breast cancer.Endocr Relat Cancer,2006,13(9):797-826.
6 Cho JY.A transporter gene(sodium iodide symporter) for dual purposes in gene therapy; imaging and therapy.Curr Gene Ther,2002,2(4):393-402.
7 Cho JY,Shen DH,Yang W, et al.In vivo imaging and:radioiodine therapy following sodium iodide symporter gens transfer in animal modeler of intracerebral glimas,Gene Ther,2002,9(17):1139-1145.
8 Shimura H,Haraguchi K,Miyazaki A,et al.Iodide uptake and experiment 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene.Endocrinology,1997,138(10):4493-4496.
9 Smit JW,Schroder-van der Elst JP,Karperien M,et al.Iodide kinetics and experimental 131I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line.J Clin Endocrinol Metab,2002,87(3):1247-1253.
10 Zhang R,Baunoch D,DeGroot LJ.Genetic immunotherapy for medullary thyroid carcinoma:destruction of tumors in mice by in vivo delivery of adenoviralvector transducing the murineinterleukin-2 gene.Thyroid,1998,8(12):1137-1146.
11 Zhang R,Straus FH,DeGroot LJ.Effective generic therapy of established medullary thyroid carcinomas with murine interleukin-2:dissemination and cytotoxicity studies in a rat tumor model.Endocrinology,1999,140(5):2152-2158.
12 Yamazaki M,Zhang R,Straus FH,et al Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12.Gene Ther,2002,9(1):64-74.
13 Soler MN,Bobe P,Benihoud K,et al.Gene therapy of rat medullary thyroid cancer by naked mitric oxide synthase II DNA injection.J Gene Med,2000,2(5):344-352.
14 Braiden V,Nagayama Y,Iitaka M,et al.Retrovirus-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter.Endocrinology,1998,139(9):3996-3999,.
15 Kitazono M,Chuman Y, Aikou T,et al.Adenovirus HSV-TK construct with thyroid-specific promoter:Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathway.Int J Cancer,2002,99(3):453-459.
16 Zhang R,DeGroot LJ.Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model:relationship of bystander effect and antitumor efficacy.Thyroid,2000,10(4):313-319.
17 Zhang R,DeGToot LJ.An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma.Endocrine Related Cancer,2001,8(4):315-325.
18 Barzon L,Pacenti M,Taccaliti A,et al.A pilot study of combined suicide/cytokine gene therapy in two patients with end-stage anaplastic thyroid carcinoma J Clin Endocrinol Metab,2005,90(5):2831-2834.
19 Ye CS,Feng G,Wang SM,et al.sFlt-1 gene therapy of follicular thyroid carcinoma.Endocrinology,2005,145(2):817-822.
20 DeGroot LJ,Zhang R.Clinical review 131:Gene therapy for thyroid cancer where do we stand?.J Clin Endocrinol Metab,2001,86(7):2923-2928.
相似文献/References:
[1]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[4]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[5]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[6]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[7]刘鹏杰,唐铭,邓智勇,等.131I治疗儿童分化型甲状腺癌期间出现低钙血症伴癫痫发作一例[J].国际放射医学核医学杂志,2015,39(4):352.[doi:10.3760/cma.j.issn.1673-4114.2015.04.017]
[8]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[9]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[10]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
[11]郭睿,李彪.钠碘同向转运体基因介导放射性碘治疗肿瘤的研究进展[J].国际放射医学核医学杂志,2010,34(3):147.
GUO Rui,LI Biao.Advances of radioiodine therapy of tumor induced by sodium iodide symporter gene[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):147.